Novartis India Share Price Jumps Up to 10% on 5 October: How a ChrysCapital Takeover, a Rs 860.64 Open Offer Almost Nobody Used and a New Retina Drug Deal Put the Stock at 2.5 Times the Offer Price

The Novartis India share price today has become one of the most volatile small caps in the market. It traded near Rs 830 in February, hit a 20% upper circuit at Rs 996.50 when the Swiss parent agreed to sell, and is now above Rs 2,100. On 5 October the stock rose as much as 7.3% to Rs 2,164.60 against a Sensex gain of 0.8%, a stock-specific move on top of the broader market recovery.

If you are searching for what lies ahead for the Novartis India stock, this article covers the ChrysCapital takeover and the Novartis India open offer, the business and its net cash, the Q1 FY27 results, the Accentrix and Pagenax distribution deal and its entry into ophthalmology, valuation, P/E and market capitalisation, the 52-week high, support and key levels, and the risks. Price data is based on NSE and BSE figures, so recheck it before acting.

Click Here – Get Free Investment Predictions

Why Is Novartis India Share Price Jumping Today?

The Novartis India share price is jumping on a mix of a market-wide rebound, a thin free float and a story of private equity ownership. Reports put the gain at 7% to nearly 10%, and the stock traded well above all its key moving averages.

The Novartis India stock was around Rs 2,018 before the rise, and the day's high of Rs 2,164.60 is about 7% above that. The analyst view in the headline is that the stock must keep above Rs 2,100 to sustain momentum, with support near Rs 1,900.

Novartis India Share Price Timeline: From Takeover to Rs 2,000

Date	Event	Novartis India share price
20 February	Novartis AG agrees to sell its 70.68% stake for about Rs 1,446 crore to a ChrysCapital-led group	Upper circuit at Rs 996.50, up 20%
11 to 24 June	Open offer for 26% at Rs 860.64 per share	Market price far above the offer
29 July	Purchase of the stake closes; Novartis AG ceases to be promoter	Near Rs 1,780 on 23 July
1 September	Stock trades after a long run	Rs 1,582
8 September	Distribution deal for retina medicines Accentrix and Pagenax	Higher by 22 September
22 September	Trading level	About Rs 2,007
5 October	Jumps up to 10%	High of Rs 2,164.60

From the Rs 830.45 close before the deal to Rs 2,164.60 is a gain of about 160% in under eight months, which is why the Novartis India share price now trades about 2.5 times the open offer price.

ChrysCapital Takeover and the Rs 860.64 Open Offer

Deal detail	Figure
Stake sold by Novartis AG	70.68% (1,74,50,680 shares)
Buyers	Consortium led by WaveRise Investments, ChrysCapital Fund X and Two Infinity Partners
Price for the stake	About Rs 1,446 crore; WaveRise paid Rs 860.64 a share, ChrysCapital entities about Rs 701.25
Novartis India open offer	Up to 26% (64,19,608 shares) at Rs 860.64, worth up to Rs 552.49 crore
Shares tendered	Only 40
Ownership after the deal (28 August)	ChrysCapital group 71%, retail 26%, institutions 3%
Delisting	No intention to delist

The open offer was priced only 3.64% above the pre-deal close of Rs 830.45. Once the Novartis India share price hit Rs 996.50, no one had a reason to tender, so the acquirers ended up with the 70.68% stake plus almost nothing from the public. The deal implied a value of about Rs 2,046 crore for the whole company, roughly 22 times FY26 profit, and the market capitalisation is now about 2.5 times that.

What Does Novartis India Do?

Novartis India is a pharmaceutical wholesaler and trader. FY26 revenue was about Rs 354 crore, all from wholesale and trading, with no manufacturing or export revenue. Revenue has been flat since FY23, and profit has slipped.

Financials	FY23	FY24	FY25	FY26
Revenue (Rs crore)	379	335	356	354
Profit after tax (Rs crore)	103	85	101	93

Q1 FY27 broke the pattern, with revenue up 18.6% to Rs 103.81 crore and net profit up 16.6%, in the first quarter under new management, which supports the Novartis India share price. One quarter is a data point and not a trend.

Check the Univest Screener for live data on pharma stocks

Accentrix and Pagenax: A Retina Deal for the Novartis India Share Price

On 8 September Novartis India agreed an exclusive promotion and distribution deal with Novartis Healthcare Private Limited for the Indian rights to Accentrix (ranibizumab) and Pagenax (brolucizumab), two retina medicines. It pays an upfront Rs 10 crore. The deal marks its entry into ophthalmology and is the first sign of a broader product plan.

The company's investor presentation talks about building an India-focused pharma platform, with Rs 668 crore of net cash as of March 2026. That is about Rs 270 per share, or roughly 13% of the current price, my calculation, and it gives the new owners room to buy brands or companies, which is the main bull case for the Novartis India share price.

Novartis India Share Price Today: Valuation and Key Numbers

Item	Figure	What it tells you
Price, 5 October high	Rs 2,164.60	About 2.5 times the open offer price
Price, 22 September	About Rs 2,007	Market capitalisation about Rs 4,940 crore
Market capitalisation at about Rs 2,100	About Rs 5,170 crore	Small-cap
Trailing P/E	About 50 times	Rich for flat revenue
Book value per share	About Rs 331	Price is about 6 times book
Dividend yield	About 1.25%	Small payout
52-week high	About Rs 2,589 (one provider)	Set during the September run
Free float	About 29%	Thin, so moves are sharp

A thin free float explains the violent moves in the Novartis India stock. With only about 29% of shares in public hands, a few buyers can push the Novartis India share price up and a few sellers can drop it just as fast.

Download the Univest iOS App or Univest Android App to track live prices of pharma and small-cap stocks.

Novartis India Share Price Levels to Watch

Level	Why it matters
Rs 2,589	52-week high from the September run
Rs 2,164.60	5 October intraday high
Rs 2,100	Level analysts want held for momentum
Rs 2,007	22 September trading level
Rs 1,900	Support cited by analysts
Rs 1,780	23 July high
Rs 860.64	Open offer price

The Novartis India share price today sits near Rs 2,100 after the Rs 2,164.60 high. These are reference levels for the Novartis India share price, not forecasts.

Risks Behind the Novartis India Share Price

Valuation: At about 50 times earnings and 6 times book, the Novartis India share price already prices a lot of growth.

Flat core business: Revenue was Rs 354 crore in FY26, almost unchanged since FY23, and profit fell about 7%.

Thin float: Only about 29% of shares trade freely, which amplifies both rallies and falls.

Execution risk: The platform plan needs acquisitions or new brands, and none beyond the retina deal is announced.

Momentum reversal: The Novartis India share price has more than doubled since February and rose 160% from the pre-deal close.

What Lies Ahead for the Novartis India Share Price?

1. Q2 FY27 results, which will show whether the 18.6% revenue growth continues.
2. New product or acquisition announcements from the ChrysCapital-led management.
3. Revenue contribution from Accentrix and Pagenax.
4. Whether the stock holds Rs 2,100 or falls back toward Rs 1,900.
5. Any change in promoter holding or float.

Conclusion

The Novartis India share price rose as much as 10% on 5 October to Rs 2,164.60, roughly 2.5 times the Rs 860.64 open offer that almost nobody used. The business is small and flat, but it has Rs 668 crore of net cash, new owners, a retina drug deal and a thin float. At about 50 times earnings, Rs 2,100 is the level to hold for the Novartis India share price and Rs 1,900 the support to watch. The Novartis India stock is a momentum story. Consult a SEBI-registered advisor before making any decision.

Frequently Asked Questions

Why did Novartis India share price jump on 5 October?

Ans. The Novartis India share price rose between 7% and nearly 10% on 5 October, hitting Rs 2,164.60 as the market rebounded and momentum built around the ChrysCapital-led ownership and new product plans.

What was the Novartis India open offer price?

Ans. The mandatory open offer was Rs 860.64 per share for up to 26% of the company. Only 40 shares were tendered because the market price was much higher.

Who owns Novartis India now?

Ans. A consortium led by WaveRise Investments, ChrysCapital Fund X and Two Infinity Partners owns about 71%. Novartis AG sold its entire 70.68% stake and is no longer a promoter, so the Novartis India share price now trades on the new owners' plans.

What does Novartis India do?

Ans. Novartis India is a pharmaceutical wholesaler and trader with about Rs 354 crore of annual revenue. It has no manufacturing or export business.

What is the Accentrix and Pagenax deal?

Ans. On 8 September, Novartis India agreed exclusive promotion and distribution rights in India for two retina medicines, ranibizumab and brolucizumab, for an upfront Rs 10 crore.

What are the key support and resistance levels for Novartis India share price?

Ans. Analysts say the stock must hold above Rs 2,100 for momentum, with support near Rs 1,900. The 5 October high was Rs 2,164.60. These are reference levels and not predictions.

Is Novartis India share price expensive?

Ans. The stock trades at about 50 times earnings and 6 times book value, with revenue flat since FY23. That is rich, and it relies on growth from the new owners.

Is Novartis India a good stock to buy now?

Ans. This article does not constitute investment advice. The Novartis India share price has strong momentum and net cash, but a high valuation and thin float. Consult a SEBI-registered financial advisor before investing.